Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

Description

The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.

Conditions

Post-Dural Puncture Headache

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.

Neostigmine and Glycopyrrolate for the Treatment of Post Dural Puncture Headache After Known Dural Puncture With a Tuohy Needle: A Pilot Study

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

Condition
Post-Dural Puncture Headache
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Post-dural puncture headache (PDPH) after documented dural puncture with Tuohy needle during placement of epidural analgesia for labor and no other explanation for headache (HA).
  • * Onset of HA within 72 hours of delivery.
  • * Patient refusal.
  • * Visual analog scale (NRS) score \< 4.
  • * History of migraine headaches.
  • * Asthma.
  • * Arrhythmia.
  • * Heart block.
  • * Myasthenia gravis.
  • * Inability to understand pain scores and other questionnaires.
  • * Inability to speak English.
  • * Contraindication to acetaminophen or NSAIDs.
  • * Temperature \> 38.5 C.
  • * Prior EBP done for this HA.

Ages Eligible for Study

18 Years to 54 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Mark Rollins, MD, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2024-12